Curvebeam AI Ltd. (AU:CVB) has released an update.
CurveBeam AI Ltd. has experienced a surge in demand, with purchase orders for their medical imaging devices jumping to 10 in the fourth quarter, bringing a forward revenue of A$4.9m into the next fiscal year. The company recently achieved FDA clearance for its enhanced HiRise imaging system and is now in the final stages of validating the technology for use with a major robotic surgical system, targeting completion early in the next fiscal year. Despite a slight dip in customer receipts in Q4, the company has a robust pipeline, including A$0.8m in receivables, and is set to begin deliveries of the newly cleared enhanced HiRise devices.
For further insights into AU:CVB stock, check out TipRanks’ Stock Analysis page.
